Crossmark

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis

Crossref DOI link: https://doi.org/10.1007/s40618-025-02655-9

Published Online: 2025-09-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chow, Junwei

Lim, Woonling

Li, Longzhou

Yu, Qiuxia

Zhong, Yu

Wang, Zihan

Shah, Syed Alfakhar Ali

Zhu, Chenyang

Yan, Shiwei

Liu, Haiyang

Hu, Xinyi

Gao, Long

Wang, Shan

Liu, Jun

Ma, Guo https://orcid.org/0000-0001-5524-7172
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82374133)

National Natural Science Foundation of China (82074109)

National Natural Science Foundation of China (81873078)

National Natural Science Foundation of China (81374051)
License Information

Text and Data Mining valid from 2025-09-12

Version of Record valid from 2025-09-12
More Information

Article History

Received: 28 March 2025

Accepted: 9 July 2025

First Online: 12 September 2025

Declarations

:

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below